Journal
CLINICAL RHEUMATOLOGY
Volume 36, Issue 7, Pages 1687-1690Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s10067-017-3688-4
Keywords
Anakinra; Autoinflammatory diseases; TNFRSF1A gene; TRAPS; Treatment
Categories
Ask authors/readers for more resources
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), caused by mutations in the TNFRSF1A gene, is the most frequent autosomal dominant autonflammatory disease displaying a relevant risk of reactive AA amyloidosis, if left untreated. Our report deals with one adult with TRAPS complicated by amyloidosis-related renal failure, treated with the recombinant human interleukin-1 receptor antagonist anakinra at a higher than conventional dosage. This treatment did not present any adverse event and led remarkably to the disappearance of all TRAPS-related manifestations and prompt decrease of laboratory abnormalities, including proteinuria. A review of the medical literature has been also considered to evaluate efficacy and safety of interleukin-1 inhibition in patients with TRAPS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available